KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Assets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on SalesTimes Interest Earned

Takeda Pharmaceutical (TAK) Enterprise Value (2018 - 2026)

Takeda Pharmaceutical has reported Enterprise Value over the past 9 years, most recently at -$6.6 billion for Q1 2026.

  • For Q1 2026, Enterprise Value fell 36.76% year-over-year to -$6.6 billion; the TTM value through Mar 2026 reached -$6.6 billion, down 36.76%, while the annual FY2026 figure was -$6.9 billion, 42.26% down from the prior year.
  • Enterprise Value was -$6.6 billion for Q1 2026 at Takeda Pharmaceutical, down from -$4.8 billion in the prior quarter.
  • Across five years, Enterprise Value topped out at -$3.2 billion in Q1 2024 and bottomed at -$7.5 billion in Q1 2022.
  • The 5-year median for Enterprise Value is -$4.8 billion (2025), against an average of -$5.3 billion.
  • Year-over-year, Enterprise Value surged 44.4% in 2023 and then crashed 51.23% in 2025.
  • Over 5 years, Enterprise Value stood at -$7.5 billion in 2022, then skyrocketed by 44.4% to -$4.2 billion in 2023, then increased by 23.77% to -$3.2 billion in 2024, then crashed by 51.23% to -$4.8 billion in 2025, then crashed by 36.76% to -$6.6 billion in 2026.
  • The last three reported values for Enterprise Value were -$6.6 billion (Q1 2026), -$4.8 billion (Q1 2025), and -$3.2 billion (Q1 2024) per Business Quant data.